CCR7 and neoplasm: Given CCR7+ DCs are a major source of PD-L1 in tumours, and the marked response of CD8+ TEX cells to anti-PD-L1 treatment, we sought to identify CCR7+ DC-mediated interactions that might promote their activation and proliferation (Fig. 5d).